Literature DB >> 7792600

A single ataxia telangiectasia gene with a product similar to PI-3 kinase.

K Savitsky1, A Bar-Shira, S Gilad, G Rotman, Y Ziv, L Vanagaite, D A Tagle, S Smith, T Uziel, S Sfez, M Ashkenazi, I Pecker, M Frydman, R Harnik, S R Patanjali, A Simmons, G A Clines, A Sartiel, R A Gatti, L Chessa, O Sanal, M F Lavin, N G Jaspers, A M Taylor, C F Arlett, T Miki, S M Weissman, M Lovett, F S Collins, Y Shiloh.   

Abstract

A gene, ATM, that is mutated in the autosomal recessive disorder ataxia telangiectasia (AT) was identified by positional cloning on chromosome 11q22-23. AT is characterized by cerebellar degeneration, immunodeficiency, chromosomal instability, cancer predisposition, radiation sensitivity, and cell cycle abnormalities. The disease is genetically heterogeneous, with four complementation groups that have been suspected to represent different genes. ATM, which has a transcript of 12 kilobases, was found to be mutated in AT patients from all complementation groups, indicating that it is probably the sole gene responsible for this disorder. A partial ATM complementary DNA clone of 5.9 kilobases encoded a putative protein that is similar to several yeast and mammalian phosphatidylinositol-3' kinases that are involved in mitogenic signal transduction, meiotic recombination, and cell cycle control. The discovery of ATM should enhance understanding of AT and related syndromes and may allow the identification of AT heterozygotes, who are at increased risk of cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7792600     DOI: 10.1126/science.7792600

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  676 in total

1.  Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.

Authors:  N H Chehab; A Malikzay; E S Stavridi; T D Halazonetis
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Purification and DNA binding properties of the ataxia-telangiectasia gene product ATM.

Authors:  G C Smith; R B Cary; N D Lakin; B C Hann; S H Teo; D J Chen; S P Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

3.  mus304 encodes a novel DNA damage checkpoint protein required during Drosophila development.

Authors:  M H Brodsky; J J Sekelsky; G Tsang; R S Hawley; G M Rubin
Journal:  Genes Dev       Date:  2000-03-15       Impact factor: 11.361

4.  ATM protein synthesis patterns in sporadic breast cancer.

Authors:  R Kairouz; R A Clarke; P J Marr; D Watters; M F Lavin; J H Kearsley; C S Lee
Journal:  Mol Pathol       Date:  1999-10

5.  Evidence for a prostate cancer-susceptibility locus on chromosome 20.

Authors:  R Berry; J J Schroeder; A J French; S K McDonnell; B J Peterson; J M Cunningham; S N Thibodeau; D J Schaid
Journal:  Am J Hum Genet       Date:  2000-05-16       Impact factor: 11.025

6.  BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures.

Authors:  Y Wang; D Cortez; P Yazdi; N Neff; S J Elledge; J Qin
Journal:  Genes Dev       Date:  2000-04-15       Impact factor: 11.361

7.  Association of Chk1 with 14-3-3 proteins is stimulated by DNA damage.

Authors:  L Chen; T H Liu; N C Walworth
Journal:  Genes Dev       Date:  1999-03-15       Impact factor: 11.361

8.  Haplotypes at ATM identify coding-sequence variation and indicate a region of extensive linkage disequilibrium.

Authors:  P E Bonnen; M D Story; C L Ashorn; T A Buchholz; M M Weil; D L Nelson
Journal:  Am J Hum Genet       Date:  2000-11-14       Impact factor: 11.025

Review 9.  Cell cycle checkpoints and their inactivation in human cancer.

Authors:  M Molinari
Journal:  Cell Prolif       Date:  2000-10       Impact factor: 6.831

10.  High-resolution transcript map of the region spanning D12S1629 and D12S312 at chromosome 12q13: triple A syndrome-linked region.

Authors:  H Lee; E Choi; Y Seomun; K Montgomery; A Huebner; E Lee; S Lau; C K Joo; R Kucherlapati; S J Yoon
Journal:  Genome Res       Date:  2000-10       Impact factor: 9.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.